US-based financial services firm Morgan Stanley has led a $15.3m Series E round for US-based NanoString Technologies, a spin out of Seattle-based Institute for Systems Biology.

US-listed investment bank Morgan Stanley has co-led a $15.3m Series E preferred stock round of financing into NanoString Technologies with investment management company Alliance Bernstein. NanoString is a spinoff from the institute for Systems Biology and develops molecular diagnostic products and tools for translational research. There were also investments from return backers Clarus Ventures, Draper Fisher Jurvetson, OVP Venture Partners, GE Healthymagination Fund, BioMed Ventures and Henri Termeer.

NanoString has raised at total of $88.8m in venture funding. NanoString’s Series…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?